Physician profile
Eric M Bonifield
NPI 1497771950
$1,899.32
in general payments reported to CMS, 2019-2025
31 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $256 · 2021: $378 · 2022: $262 · 2023: $158 · 2024: $212 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.59 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.55 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $201.44 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $157.89 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $155.40 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $75.24 | 2021-2025 | Nexplanon |
| Sage Therapeutics, LLC | $71.29 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $64.26 | 2021-2022 | |
| Pfizer INC. | $58.07 | 2019-2025 | |
| Lupin INC. | $44.23 | 2019-2020 | |
| Covidien Lp | $43.63 | 2019 | |
| Exact Sciences Corporation | $42.19 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $41.29 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.19 | 2019-2025 | |
| Boston Scientific Corporation | $40.26 | 2019 | |
| Medtronic, INC. | $35.31 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.73 | 2023-2024 | Accrufer |
| Myovant Sciences INC. | $30.42 | 2021-2022 | |
| Therapeuticsmd, INC. | $29.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.71 | 2019-2020 | |
| Avion Pharmaceuticals | $27.59 | 2019-2022 | |
| Dysis Medical, INC. | $21.19 | 2022 | |
| Davol INC. | $19.44 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.87 | 2025 | Qelbree |
| Medicem INC. | $16.03 | 2021 | |
| Agile Therapeutics, INC. | $15.49 | 2021 | |
| Sumitomo Pharma America, INC. | $13.81 | 2023 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $13.61 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.48 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.39 | 2022 | |
| Meditrina | $12.97 | 2021 | |
| Allergan, INC. | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bonifield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.